FDA Denies Bayer Petition For Aspirin As Primary Prevention Of Heart Attack, Stroke
This article was originally published in The Tan Sheet
Executive Summary
Aspirin’s potential to prevent a first stroke or heart attack if used regularly does not outweigh the risks, including increased bleeding in the stomach and brain, FDA tells Bayer Healthcare in a May 2 letter denying the firm’s request to market the drug for primary prevention.
You may also be interested in...
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.